Table I.
Baseline characteristics of DLBCL patients
| No DM, No metformin | % | DM, No metformin | % | DM, Metformin | % | P value | |
|---|---|---|---|---|---|---|---|
| Age (years) | <0.01 | ||||||
| ≤60 | 317 | 41.3 | 8 | 14.8 | 13 | 27.1 | |
| >60 | 450 | 58.7 | 46 | 85.2 | 35 | 72.9 | |
| Gender | 0.92 | ||||||
| Male | 440 | 57.4 | 31 | 57.4 | 29 | 60.4 | |
| Female | 327 | 42.6 | 23 | 42.6 | 19 | 39.6 | |
| ECOG PS | 0.14 | ||||||
| <2 | 685 | 89.5 | 44 | 81.5 | 41 | 85.4 | |
| ≥2 | 80 | 10.5 | 10 | 18.5 | 7 | 14.6 | |
| LDH | 0.14 | ||||||
| Normal | 310 | 45.4 | 21 | 43.8 | 14 | 30.4 | |
| Elevated | 373 | 54.6 | 27 | 56.3 | 32 | 69.6 | |
| Extranodal sites | 0.02 | ||||||
| ≤1 | 616 | 80.3 | 36 | 66.7 | 42 | 87.5 | |
| >1 | 151 | 19.7 | 18 | 33.3 | 6 | 12.5 | |
| Ann Arbor stage | 0.05 | ||||||
| I-II | 337 | 44.0 | 16 | 29.6 | 16 | 33.3 | |
| III-IV | 429 | 56.0 | 38 | 70.4 | 32 | 66.7 | |
| IPI score | 0.01 | ||||||
| 0–1 | 294 | 38.3 | 11 | 20.4 | 10 | 20.8 | |
| 2 | 212 | 27.6 | 14 | 25.9 | 18 | 37.5 | |
| 3 | 188 | 24.5 | 18 | 33.3 | 14 | 29.2 | |
| 4–5 | 73 | 9.5 | 11 | 20.4 | 6 | 12.5 | |
| Cell of origin | 0.17 | ||||||
| GCB | 308 | 59.2 | 29 | 74.4 | 19 | 63.3 | |
| Non-GCB | 212 | 40.8 | 10 | 25.6 | 11 | 36.7 | |
| Frontline Therapy | 0.55 | ||||||
| Immunochemotherapy | 712 | 93.4 | 51 | 94.4 | 43 | 89.6 | |
| Other therapy | 50 | 6.6 | 3 | 5.6 | 5 | 10.4 | |
| BMI (kg/m2) | <0.01 | ||||||
| <25 | 221 | 29.4 | 5 | 9.3 | 3 | 3.6 | |
| ≥25 but <30 | 298 | 39.6 | 18 | 33.3 | 12 | 25.0 | |
| ≥30 | 233 | 31.0 | 31 | 57.4 | 33 | 68.8 |
BMI: body mass index; DLBCL: diffuse large B-cell lymphoma; DM: type 2 diabetes mellitus; ECOG PS: Eastern Cooperative Oncology Group performance status; GCB: germinal centre B cell; IPI: International Prognostic Index; LDH: lactate dehydrogenase.